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ABSTRACT
Forster, Jana L. Synthesis and Evaluation of N-(9’-Acridinyl)-O-phenylhydroxylamines.
Unpublished Master of Science Thesis, University of Northern Colorado, 2020.

Anilinoacridines are a class of compounds that are known to intercalate DNA. This class
of compounds can be used as a target therapy to combat cell growth and replication. The
anilinoacridines, DNA, and topoisomerase II will form a ternary complex that results in
numerous strand scissions leading to apoptosis. Previous research has shown that the
anilinoacridines can have a short half-life and produce harmful side products as a result of
hydrolysis. The half-life could increase if this structure was slightly altered by making a
molecule that does not readily hydrolyze. N-(9’-Acridinyl)-O-phenylhydroxylamines can be
synthesized in three steps starting with commercially available aryl bromides and a protected
hydroxylamine using catalytic palladium. This organometallic reaction gives a simple way to
prepare an O-substituted hydroxylamine. After hydrolysis, the resulting product can then be
coupled to 9-chloroacridine to form the target molecules. Spectroscopy, such as 1H NMR, 13C
NMR, COSY, and HSQC were used to determine the structure and purity of each synthesized
product. The title compounds were then analyzed and evaluated for their binding to DNA using
viscosity. Unfortunately, due to the difficulty of purification of the title compounds, viscosity
measurements were attempted but lead to inconclusive results.
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CHAPTER I
INTRODUCTION
The American Cancer Society estimates that some of the earliest documented cases of
cancer date to 3000 BC in an ancient Egyptian textbook from a trauma surgery (American
Cancer Society, 2014b). Even so, today cancer is still the second leading cause of death after
heart disease. Cancer, defined as a normal cell’s loss of function of the mechanisms in charge of
growth and multiplication, is often characterized as uncontrolled cell growth (Patrick, 2005).
During cellular replication, a replication error could occur in a specific gene resulting in one of
three outcomes: repair, continue replication, or apoptosis. Most of the time, the cell repairs the
damage. Alternatively, the cell in some cases can continue replication and survive because the
mutation is not lethal. In some cases, the mutation leads to uncontrolled cell growth and the cell
becomes cancerous. In other words, cancerous cells can skip or ignore important checkpoints
during cellular replication.
Since there are many different types of cells and many different mutations that can affect
cell growth, it is very difficult to treat all cancer with the same treatment. In fact, there are over
two hundred types of cancer that are known and likely countless others types that are not yet
known. So even if a treatment works on one type of cancer, it may be unsuccessful on other
types of cancer (Patrick, 2005).
In 2019, over 1.9 million new cancer cases were diagnosed in the United States (Siegel,
Miller, Jemal, 2020). In other words, 0.58% of the U.S. population was diagnosed with cancer in
2019. That same year, over 620,000 people (0.19% of the U.S. population) died of their cancer in
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the United States (Siegel et al., 2020). The Centers for Disease Control and Prevention estimates
about 1.8 million new cancer cases will be introduced in 2020 and that 606,000 deaths will result
(Centers for Disease Control and Prevention, 2018). In other words, the death rate from cancer is
about 34%. It is evident that cancer continues to be an ongoing health issue.
Most research on treating and curing cancer is focused on a specific target within the
cancerous cells. For example, one target is the mechanism of replication. Therapies that target
that mechanism can include the use of drugs, X-rays, or other methods. Other examples of
specific chemotherapies used to treat specific targets are shown in Figure 1.1. Each of the drugs
in Figure 1.1 targets a different characteristic of a particular cell line.

Figure 1.1: Different examples of target therapies. Oestrogen (Oestradiol) are hormone based
therapies, combrestastain A-4 is a drug that acts on structural proteins, lonafarnib inhibits
signaling pathways, and amsacrine acts directly on nucleic acids (Patrick, 2005).
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One identified target therapy for cancer cells is cellular DNA. This target was selected
because some cancer cell lines grow and replicate faster than many somatic cell types (American
Cancer Society, 2014a). Because DNA plays an important role in replication and translation
events within a cell, DNA can be used as a target for a drug to bind and inhibit those vital
functions. For example, it is well-known that aminoacridines intercalate DNA (Gao, B. Li,
Zhang, Sun, L. Li, X. Li, Chen et al., 2015). Thus, many aminoacridine derivatives have been
evaluated for their anticancer effects. Some research has provided evidence that 9aminoacridines also interact with topoisomerase II, a key cellular enzyme used in supercoiling
(see Figure 1.2). The resulting 9-aminoacridine-DNA-topoisomerase II complex antagonizes the
re-annealing step during supercoiling of the DNA. The ability of the 9-aminoacridine to ‘walk’
along the DNA strand results in numerous lethal strand scissions that lead to cell apoptosis (see
Figure 1.3).

Figure 1.2: Represents DNA and topoisomerase II complex. Topoisomerase will attach to DNA
and will snip a strand of DNA, then topoisomerase II will pass one strand of DNA through the
other and will re-bind the DNA back together creating a supercoil (Lodish, Berk, Zipursky,
Matsudaira, Baltimore, Darnell, 2000).
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Figure 1.3: Represents DNA, topoisomerase II, and ternary drug complex. The drug would
allow the first two steps to occur, but would inhibit the reannealing process leading to multiple
strand scissions which ultimately results in apoptosis (Denny, 2002).
Ketron and coworkers studied the derivatives of amsacrine (AMSA), a 9-anilinoacridine,
for its potential use as an antineoplastic (anticancer) agent. m-Amsacrine (m-AMSA) (4), shown
in Figure 1., was selected as the better derivative of AMSA due to its ability to intercalate into
the DNA base pair stack and also antagonize topoisomerase II. The outcome has resulted in mAMSA being admitted to multiple clinical trials to treat hematological cancers, refractory acute
lymphocytic and nonlymphocytic leukemia, and Hodgkin’s and non-Hodgkin’s lymphomas.
(Ketron Denny, Graves, Osherooff, 2012).
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Figure 1.4: Structure of Amsacrine (AMSA), o-AMSA, and m-AMSA.
Even though the therapeutic use of m-AMSA (4) is successful, there are still ways to
improve on the effectiveness of the molecule. The most effective improvement is based on the
fact that m-AMSA has a short half-life (32 minutes in fresh mouse blood) under biological
conditions. In addition, the initial metabolism of m-AMSA results in the formation of
compounds which are toxic. This degradation can occur via hydrolysis or thiolysis whose
mechanism is illustrated in Figure 1. (Denny, 2002).
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Figure 1.5: Hydrolysis mechanism of m-Amsacrine
Since the substituent on the aniline leaving group is electron withdrawing, it helps
stabilize the amine as it dissociates from the acridine in the hydrolysis mechanism. This is
problematic because the degradation leads to a toxic product; a substituted aniline. However, if
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oxygen was added between the amine and the phenyl in the leaving group, the hydrolysis would
not occur as easily. This is because the oxygen’s lone pairs would destabilize the adjacent lone
pair on the amine nitrogen, resulting in a less labile leaving group. If the resulting Ophenylhydroxylamine leaving group will not leave as easy, it will more likely stay intact as the
therapeutic agent.
N-(9’-Acridinyl)-O-phenylhydroxylamines
One way to overcome hydrolysis or thiolysis of the anilinoacridine is by inhibiting the
leaving group ability of the 9-anilino group as noted above (Denny, 2002). An acridine
substituted with the phenoxyamino group (compound 20 where R = Ph in Figure 1.6) should
maintain similar intercalation of the DNA as compared to an acridine substituted with an anilino
group, but offer a reduced hydrolysis rate (Figure 1.).

Figure 1.6: Aniline and a hydroxylamine with their corresponding pKa values (Chemical Book,
n.d.). The phenylamine is a better leaving group than the hydroxylamine. Because of this, the
phenylhydroxylamine will not undergo hydrolysis as easily.
The pKa of the above molecules could also indicate the ability for that molecule to
dissociate from the acridine. Since the estimated pKa of the O-phenylhydroxylamine is higher
than the pKa of aniline, the O-phenylhydroxylamine is more basic and would be forced to bind
to the acridine and not dissociate. While the difference in the pKa values appears to be
insignificant, a 0.1 unit change in the pKa would equate to halving the rate of hydrolysis. Thus,
the resulting drug’s half-life in the body would increase, making the drug more effective. This
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may result in lowering of the therapeutic dose for the drug, which would also lower the risk of
death due to the toxicity of the compound.
One method to test the proposed phenoxyaminoacridine’s ability to intercalate to DNA
would be to evaluate its effect on the viscosity of DNA solutions (Kerby & Mosher, 2016).
Viscosity measures a solution’s ability to flow. As intercalation events increase, the DNA strands
lengthen which causes an increase in the viscosity of the solution. In other words, as the viscosity
increases of a drug-DNA solution, the number of intercalation events, or the strength of those
events, also increases. Different substituents on the phenoxyaminoacridine skeleton were used to
fine-tune the intercalation.
Figure 1.7 illustrates a series of compounds that were prepared in this study to evaluate
the effectiveness of the phenoxyaminoacridines to intercalate DNA. The substituents were
selected to study the span of electronic effects of each substituent to determine the effect on
intercalation. The methoxy group was chosen as the most electron releasing in the series and the
nitro group was chosen as the most electron withdrawing. The specific electronic effects will
then be correlated to the viscosity of a drug-DNA solution.

Cmpd
21a
21b
21c
21d
21e

Figure 1.7: Structure of N-(9’-acridinyl)-O-phenylhydroxylamine.

R
-OCH3
-CH3
-H
-Cl
-NO2
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CHAPTER II
REVIEW OF LITERATURE
Evaluation of Deoxyribonucleic Acid
(DNA) Binding
Denny studied acridine derivatives and their ability to bind to DNA. He concluded that
there are three main factors for DNA interaction: mode of binding, strength of binding, and
kinetics of binding (Denny, 2002). There are two types of binding: electrostatic binding (or
groove binding) and intercalation. Binding to the DNA backbone via electrostatic association
causes minimal changes to the DNA structure. Binding to DNA by insertion between adjacent
base pairs (intercalation) results in significant structural changes including lengthening,
stiffening, and unwinding of the DNA. Since there can be more noticeable changes when a
molecule intercalates DNA, the binding of a molecule such as the title N-(9’-acridinyl)-Ophenylhydroxylamines can be evaluated by measuring the structural changes to DNA.
In many cases, the strength of the drug-DNA association is directly correlated to the
chemotherapeutic potency and to biological effects of the drug in vivo. In other words, the longer
the residence time of a drug at a DNA binding site, the more effective the drug.
The two modes of binding to DNA have different energies associated with them. The
actual energy is highly dependent upon the appropriate pKa of the drug and the ability of the drug
to interact with the DNA base pairs. For example, Denny suggested that amsacrine will
intercalate with DNA’s minor groove via - interactions (see Figure 2.1). The planar portion of
the amsacrine (an acridine heterocycle (23)) exists as a cation at physiological pH which can
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then insert and be held close to the anionic phosphate backbone. The strong interactions
associated with intercalation occur by - stacking and charge transfer between the ligand and
DNA bases. The pendant (22) portion of the amsacrine interacts with the phosphate backbone via
hydrogen bonding. The pendant can also bind with the major or minor groove depending on how
the acridine nucleus is oriented in the base pair stack. Because the acridine nucleus takes up
space during intercalation, the DNA is elongated. The length of the DNA, which can be
indirectly measured via viscosity, could be measured with and without the drug intercalated to
determine if the drug was successful with interacting with DNA. Different substituents could be
added to the molecule to determine the molecule that has the most effect on the DNA.

Figure 2.1: Acridine intercalated with DNA base pair via - interactions. The pendant (left) is
interacting with the DNA backbone whereas the acridine (right) is intercalating the DNA.
(Belmont & Dorange, 2008).
Denny defines intercalation as a polyaromatic insertion between DNA base pairs which
can bind by stacking and charge transfer. Intercalation helps DNA base pairs interact with the
acridine promoting cytotoxicity and ultimately apoptosis. This is because amsacrine can form a
ternary complex with DNA and topoisomerase II (Denny, 2002).
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Other research suggests that 9-anilinoacridines derivatives such as nitracrine and N-[2(dimethylamino)ethyl]-acridine-4-carboxamide (DACA) can also intercalate with DNA (Kumar,
A. Sharma, S., Sharma, Silakari, Singh, Kaur, 2017). However, Denny (2002) focused mainly on
m-AMSA (4) because it was approved for use in patients (Ketron et al., 2012).
Ketron and coworkers varied the AMSA concentrations while keeping the DNA
concentrations constant as a way to study intercalation. Specifically, he studied the effects of
different AMSA concentrations on DNA via a topoisomerase I based assay. The DNA fluctuated
between fully supercoiled or fully relaxed. His group concluded that o-AMSA (6) fully relaxed
the DNA at the lowest concentration (10M) compared to m-AMSA (25M) (Ketron et al.,
2012). This could be due to the fact that m-AMSA restricts rotation of the headgroup which
increases the effectiveness.
Researchers have found a few different ways to test 9-anilinoacridine’s ability to
intercalate DNA. Common ways to evaluate are MTT assays (IC50 test) or thermal denaturation.
An MTT assay can be used to determine the LD50 of the drug which correlates to how effective
the drug was to kill a cell. This is a colorimetric assay that is used to measure metabolic activity
to determine cell viability, proliferation, and cytotoxicity (Sigma Aldrich, n.d.). By using a 96
well plate with a fixed number of cells in each well, the concentration of drug can be varied in
each well. The NADP-H dependent oxidoreductase enzyme will then react with the MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow in color) and reduce it to
formazan (a purple color). If the well remains a yellow color the cells are dead but if the wells
are a purple color, the cells are viable. This assay could be quantified by determining the LD50 by
measuring the absorbance at 562 nm which then correlates to the number of viable cells.
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Thermal denaturation is the temperature at which half the DNA has transitioned from
double-stranded to single-stranded (Zhang, Sun, Kong, Xu, 2015). Thermal denaturation is
useful as it can help determine the strength and mode of binding of the DNA and drug. This is
accomplished by measuring the thermal denaturation of the DNA alone and then measuring the
thermal denaturation of the DNA-drug complex. The greater the Tm value, the more effective
the drug was at inhibiting conversion of double to single stranded DNA. The greater the
temperature needed to convert double to single stranded DNA (a positive difference) signifies
that the drug is making the DNA more stable which would inhibit the DNA to replicate during
cell replication. Thermal denaturation measurements can be taken using a 1:1 ratio of DNA to
drug solution and measuring the absorbance at different temperatures. The difference in the two
thermal denaturation temperatures (Tm) can also be correlated to the effect the different
substituents have on the ability of the drug to bind to DNA.
Synthesis of Hydroxylamines
Castellino and Rapoport studied a general method for the synthesis of phenoxyamines
(27). The synthesis consisted of an amine exchange with 2,4-dinitrophenoxyamine (DNPHA)
(24) as a good leaving group (see Figure 2.2). This compound was used for three reasons:
stability, ease of synthesis, and success in other amine exchange reactions (Castellino &
Rapoport, 1984). Castellino and Rapoport noted that the amine acceptor, a substituted phenol,
would have to be electron withdrawing for the leaving group (26) to leave, although some
electron donating substituents may provide synthetically useful yields. The overall reaction
started by using NaH and dimethylformamide (DMF) with a substituted phenol (25) followed by
addition of DNPHA (24).
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Figure 2.2: Overall synthesis of phenoxyamines (Castellino & Rapoport, 1984).
Castellino and Rapoport also studied the correlation of pKa to percent yield and
determined that there was a slight direct correlation. The percent yields were determined using
1

H-NMR to eliminate loss of product during isolation. Methyl resonances were analyzed and the

integrated weights were used to obtain the percent conversion (see Table 2.1).
Table 2.1:

Selected Data From the Synthesis of Phenoxyamines, 27 (Castellino & Rapoport, 1984).
R
R2
R3
H OCH3
H
OTs
H
OMs
OTs
H

Percent Conversion (%)
R4
R5
H OCH3
H
H
H OMs
H
H

13
88
100
88

Petrassi, Sharpless, and Kelly used N-hydroxyphthalimide (28) and phenylboronic acid
(29) to synthesize a range of hydroxylamines (27) as shown in Figure 2.3 (Petrassi, Sharpless,
Kelly, 2001). The reaction was performed using a copper salt catalyst with a base and molecular
sieves in dichloromethane. Petrassi and coworkers proposed that the phenylboronic acid formed
a complex with the copper which then transmetalated forming a phenylcopper complex. Then
pyridine, acting as this base in the reaction, formed a complex with copper. Finally, reductive
elimination from copper resulted in the coupling of the phenyl group to the hydroxylamine
oxygen to form the product (Petrassi et al., 2001).
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Figure 2.3: Synthesis of hydroxylamine using a copper-mediated cross coupling (Petrassi et al.,
2001).
Along with determining the most effective copper salt, Petrassi and coworkers also took
steps to optimize the amine base for the cross coupling reaction. The most efficient reaction used
CuCl as the catalyst with pyridine as the base. Using CuCl as the catalyst gave up to a 91% yield
(see Table 2.2). This research provided an improved way for making a hydroxylamine with mild
reaction conditions and the ability to easily add different substituents. However, Petrassi and
coworkers expressed the need for future research as this reaction required two equivalents of the
appropriate phenylboronic acid. Furthermore, this reaction did not work with an ortho
heteroatom substituent or a second boronic acid functionality on the phenylboronic acid.
Table 2.2:

Selected Results From Petrassi and Coworkers Using CuCl (Petrassi et al., 2001).
R

H

Yield (%) 90

CF3 OMe Br
65

37

73
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To improve upon the hydroxylamine synthesis from Sharpless and Kelly (Petrassi et al.,
2001), Ghosh and Olofsson (2014) explored a metal free synthesis using a diaryliodonium salt.
The first of the improvements was to employ N-hydroxysuccinimide (32) instead of Nhydroxyphthalimide (28). This increased the atom economy of the reaction. To rate their success,
they compared results to N-hydroxyphthalimide. Ghosh and Olofsson determined that the most
effective synthesis occurred in an oil bath when N,N-dimethylformamide (DMF) was used as the
solvent at 60C. The oil bath was optimal for the long reaction times. Furthermore, potassium
tert-butoxide produced the highest percent yields (see Figure 2.4). Ghosh and Olofsson used a
range of symmetric and asymmetric diaryliodonium salts (35-37) to study different substituents
on the product. The selected substituents were alkyl, halide, methoxy, and nitro.

Figure 2.4: Synthesis of aryloxyamines under the most optimal reaction conditions with selected
diaryliodnoium salts (Ghosh & Olofsson, 2014).
Once the N-aryloxysuccinimides were made, Ghosh and Olofsson employed a new route
to isolate the product, as shown in Figure 2.5. One challenge in Sharpless and Kelly’s synthesis
was the use of hydrazine to cleave the hydroxylamine from the phthalimide. Hydrazine is
relatively unstable and toxic, which caused issues during the isolation of the product. So instead
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of using hydrazine, Ghosh and Olofsson used a hydrolysis with a hydroxylamine to form the
product in good yields (Figure 2.5). Even though the synthesis performed by Ghosh and
Olofsson was successful, the synthesis was done using sub-millimole concentrations and was
never scaled up.

Figure 2.5: Hydrolysis of aryloxysuccinimides to aryloxyamines. Ghosh and Olofsson
determined how to isolate the product without using hydrazine (Ghosh & Olofsson, 2014).
To improve on Petrassi’s synthesis, a parallel synthesis to form O-aryloxyamines were
made using fluorous tag technology (Gaucher-Wieczorek, Maillard, Badet, Durand, 2010).
Fluorous tags, otherwise known as an addition of a perfluoroalkyl chain, were used as an
alternative synthesis because of their high thermal and chemical stability and the reaction can be
performed using common solvents creating a homogeneous solution (Figure 2.6). In addition,
using a fluorous tag allows for an easier purification and solid phase extraction process (F-SPE).
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Figure 2.6: Alternative O-aryloxyamine synthesis using a fluorous tagged Nhydroxyphthalimide (Gaucher-Wieczorek et al., 2010).
The goal was to prepare a parallel synthesis by expanding the N-hydroxyphthalimide (28)
to aryl boric acids. This, however, failed and proved that the N-hydroxyphthalimide was
necessary for the reaction to be successful. Still wanting to use fluorous tags, GaucherWieczorek and coworkers made a fluorous tagged N-hydroxyphthalimide (40). This was
achieved by optimizing the reaction conditions where the reaction was completed with Cu(OAc)2
and pyridine in benzotrifluoride (BTF) at 20 °C. Although this method gave reliable results, it
was very time consuming.
Maimone and Buchwald prepared O-arylhydroxylamines using palladium as a catalyst.
Their goal was to improve a copper-based method by improving yields, shortening reaction
times, adding heterocyclic substrates, and eliminating aryl iodides and aryl boronic acids
(Maimone & Buchwald, 2010). To achieve their goal, Maimone and Buchwald used ethyl
acetohydroximate (44) instead of using N-hydroxyphthalimide (28) (see Figure 2.7).

Figure 2.7: Synthesis of O-aryloximes using palladium (Maimone & Buchwald, 2010).
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First, Maimone and coworkers experimented with different ligands to determine a
suitable ligand, shown in Figure 2.9. Some of the ligands used were t-BuBrettPhos (46), Brett
Phos (47), t-Bu (48), t-BuXPhos (49), XPhos (50), and JohnPhos (51). One major consideration
was selecting a ligand that promoted C-O reductive elimination under mild conditions but also
showed a high activity and thermal sensitivity to an N-O linkage (Maimone & Buchwald, 2010).
The ligands that were found to be most effective were the bulky biarylphosphines, 46 and 49,
shown in Figure 2.8.

Figure 2.8: Ligand evaluation (Maimone & Buchwald, 2010).
The overall reaction involved a palladium-catalyzed C-O coupling between different
substituted aryl halides. The ester oxime product was then converted into the Ophenylhydroxylamine (27) (see Figure 2.9) using mild acid hydrolysis in dioxane.
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Figure 2.9: Oxime hydrolysis to form O-arylhydroxylamine with different R groups. Overall
percent yield is shown from select data (Maimone & Buchwald, 2010).
Synthesis of N-(9’-acridinyl)-O-benzylhydroxylamines
Previous work to prepare a series of N-(9’-acridinyl)-O-benzylhydroxylamine (60)
derivatives was accomplished. Those compounds were also evaluated for their biological activity
using MTT assays and DNA thermal denaturation measurements (Johnson, Duncan, Mosher,
2018). The synthesis of these compounds included three main steps starting from commercially
available N-hydroxyphthalimide (28) and a substituted benzyl chloride (56), shown in Figure
2.10. The process involved preparation of hydroxylamines (58) which was made via a SN2
reaction. The hydroxylamines were then coupled to 9-chloroacridine (59) to obtain the final
products. The final products were purified using column and radial chromatography. 9chloroacridine could be purchased or made using N-phenylanthranilic acid and phosphorus
oxychloride (Horning Horning, Allen, Drake, Hamilton, Shriner, Smith, Snyder, 1955).
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Figure 2.10: Synthesis of N-(9’acridinyl)-O-benzylhydroxylamine derivatives (Johnson et al.,
2018).
An interesting feature of the target molecule included the proton resonances of the
acridine unit in the 1H-NMR. A crystal structure of one of the derivatives revealed that the
molecule existed as the oxime (61) rather than as the hydroxylamine (60c), see Figure 2.11
(Johnson et al., 2018). The implications of this structural difference are that the oxime tautomer
(61) would be less likely to undergo hydrolysis at C9 that the hydroxylamine tautomer (60c).
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Figure 2.11: Possible configurations of the product (Johnson et al., 2018).
Another challenge was that substitution on the O-benzyl group had very little effect on
the overall intercalation of the molecule with DNA. This was likely due to the lack of resonance
from the benzyl group to the acridine subunit (Johnson et al., 2018). Johnson and coworkers
came to this conclusion because there was no significant trend to the viscosity data (shown in
Table 2.1). However, it was evident that different substituents had an effect on the ring as the
viscosity varied with different substituents (Johnson et al., 2018). Resonance allows the acridine
and phenylhydroxylamine to communicate during intercalation with the DNA.
So, to make an O-aryl group on the hydroxylamines, a different approach is needed. To
ensure that resonance between the regions of the molecule occurs, the benzyl carbon must be
removed. With an increase in resonance, phenoxyaminoacridine can more effectively intercalate
with DNA.
Viscosity
Viscosity measures a liquid or a solution’s ability to flow based on internal friction
(Zhang et al., 2015). Insertion of different drugs between nucleotide base pairs would affect the
viscosity of a solution. Intercalation of a particular drug into the DNA backbone would lengthen
the DNA. The longer DNA would be expected to increase the viscosity of the DNA solution.
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Therefore, viscosity data can be used to determine the degree of intercalation of a drug. This
means that the more a compound such as N-(9’-acridinyl)-O-phenylhydroxylamine intercalates
with DNA, the higher the viscosity.
Lerman studied the viscosity of 9-aminoacridines and acridine dyes when combined with
DNA to determine the acridines’ ability to intercalate to DNA (Lerman, 1961). Intercalation is
dependent on the length and width of the molecule which then affects the viscosity. Lerman
determined there was a difference in viscosity of DNA solutions with an intercalation agent,
(such as pinacyanol, proflavine, or acridine orange) when compared to solutions without the
intercalator. In addition, if the intercalation agents were charged, the viscosity also changed. 9Aminoacridines and acridine dyes were studied because they have been known to exist as cations
at a physiological pH in addition to being planar and aromatic. This allows them to interact with
the deoxyribose-phosphate backbone via hydrogen bonding which then elongates DNA.
In 1982, Wilson and coworkers studied the effects of how different planar and aromatic
compounds, such as acridines, bind with DNA. Specifically, they looked at the differences
between monointercalation and bisintercalation with different compounds which have an effect
on “neighbor exclusion” or limiting the number of binding sites. To determine this, a viscometric
titration was performed to allow the unwinding angle to be calculated using the drug and the
DNA concentration. From there, different monointercatators or bisintercalators could be studied
to determine each unwinding angle. Small amounts of dimethyl sulfoxide (DMSO) were used to
dissolve the compounds and the drug stock solutions had a concentration of 5 x 10-5 M. Wilson
and coworkers determined there was a correlation between the unwinding angle and how the
compound bound to DNA. The bisintercalators had an unwinding angle of approximately twice
the size of monointercalators (Wilson, Keel, Jones, Mosher, 1982).
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Wilson and coworkers also used viscosity to determine the degree of intercalation by
observing the length increase of DNA and drug against a DNA free sample. The amount of
intercalation was calculated by dividing the length of the DNA and drug sample by the DNA free
sample. It was determined that acridines could bind to DNA via bisintercalation, but the degree
of binding relied heavily on the substituent on the acridine. In addition, it was concluded that the
monomer compounds were more successful in lengthening the DNA.
Kerby and Mosher continued the work of Johnson and Mosher and studied the viscosity
of the N-(9’acridinyl)-O-benzylhydroxylamine derivatives with DNA (Kerby & Mosher, 2016).
The viscosity of calf thymus (sodium salt) DNA and DNA-drug solutions were measured to
determine if and how much the acridine derivatives intercalated with DNA. This was completed
using a 1:1 molar ratio of genomic calf-thymus DNA to drug. The acridines were dissolved in
small amounts of DMSO and then added to the DNA solutions dissolved in a pH 6 buffer
system. It was determined that the substituents on the hydroxylamine had an effect on the
intercalation that matched a similar trend observed with MTT assays, but there was no direct
correlation of the electronic character of the substituent with the viscosity. A summary of the
viscosity is shown in Table 2.3.
Table 2.3:

Selected viscosity data from Kerby and Mosher (2016).
Cmpd

R

Relative Viscosity

60a
60b
60c
60d
60e

H
m-NO2
o-CH3
p-Br
o-Cl

1.000
1.020
1.025
1.032
1.033
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CHAPTER III
METHODOLOGY
General Methods
All chemical compounds were obtained from Sigma Aldrich Chemical Company and
were used without purification. 4-Bromoanisole, 4-bromotoluene, 1-bromo-4-chlorobenzene, 1bromo-4-nitrobenzene, anhydrous toluene, solid phenol, and cesium carbonate were stored at
room temperature. Allylpalladium(II) chloride dimer ((allylPdCl)2), and O-phenylhydroxylamine
were stored in the refrigerator (between 2-5 C) under argon. Ethyl acetohydroxamate and 9chloroacridine were stored in the refrigerator (between 2-5 C) and warmed to room temperature
before use.
For removal of solvents via rotary evaporation, an IKA Rotary Evaporator RV-10 was
used. The rotary evaporator was used to remove and reclaim solvents at a reduced pressure. The
controlled water bath was set between 40 – 60 C (depending on the solvent) and the product
spun at 155-185 rpm. The rotary evaporator contained a recirculating ice water bath to cool the
vertical condenser and reclaim solvents.
Each step in the synthesis required chromatography to separate and purify the products.
Both column and radial chromatography techniques were used. For column chromatography, the
Yamazan Smart Flash EPCLC AI-580S was used. Using normal phase silica gel columns, any
UV active compounds would be identified as they exited the system and automatically
fractionated into individual flasks. Two silica gel columns were used: an inject and universal
column. The inject column, size small, (catalog number W826) was used to preserve the

25
universal column. The universal column, size medium or large, (M: catalog number UW002 L:
catalog number UW104) was used as the main column for separating the products. The solvent
was then removed using the rotary evaporator. The Yamazen Smart Flash was automated but
used a relatively large amount of solvent.
For radial chromatography the Harrison Associates ChromatotronTM was used. A glass
disk coated with silica gel 60 PF254 containing gypsum (kieselgel 60 PF254 gipshaltig) spins
forcing the eluent to the outside edge of the plate along with the separated compounds. The more
polar compounds will interact with the silica gel keeping them inside the chromatotron longer.
The more non-polar compounds interact with the eluent which forces the compounds to the edge
of the plate faster. A short-wave 254 nm UV-lamp was used to locate the fractions and each
fraction was manually directed into a different receiving flask. The solvent was also removed
using the rotary evaporator. The plate was cleaned with methanol. Care was taken to ensure the
methanol completely evaporated before the plate was used again, to avoid the plate cracking or
breaking. If an aminoacridine needed to be separated, the plate was cleaned using methanol and
5% triethylamine (TEA). TEA aided in forcing acridone off the plate. Radial chromatography
used less solvents and it was easier to distinguish between different fractions compared to flash
chromatography.
All nuclear magnetic resonance (NMR) spectra were obtained on a Bruker Avance II
spectrometer (400 MHz for 1H). The spectra used deuterated solvents such as CDCl3 and
acetone-d6. Residual un-deuterated solvent was used to identify the spectrum window. Both 1D
(1H, 13C) and 2D (COSY and HSQC) experiments were performed on the spectrometer.
A RheoSense MicroViscometer (H1310-00329) was used for viscosity testing. The
deoxyribonucleic acid sodium salt from calf thymus (genomic calf-thymus DNA) solutions used
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in the viscosity studies were quantified after dissolution in a phosphate buffer at pH 6 using a
wavelength of 259 nm and known molar absorptivity of 5800 M-1 cm-1. Deoxyribonucleic acid
sodium salt from calf thymus (genomic calf-thymus DNA) was purchased from Sigma Aldrich.
Synthesis of Target Compounds
A series of N-(9’-acridinyl)-O-phenylhydroxylamines (21a-e) were prepared in three
main steps starting with commercially available compounds (see Error! Reference source not
found.). Compound 27c (R = H) was commercially available and was used to prepare compound

21c directly.

Cmpd
21a
21b
21c
21d
21e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.1: Overall Synthesis (Johnson et al., 2018) (Maimone & Buchwald, 2010).
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The first step, shown in Figure 3.2, was to make a series of ethyl-N-phenoxyacetamidates
(45) using the method outlined by Maimone and Buchwald (2010). Their method involved
treating the appropriately substituted aryl bromide (43) with allylpalladium(II) chloride dimer
((allylPdCl)2) and ethyl acetohydroxamate (44). The specific derivatives varied only in the
substituent located in the para-position on the aryl ring. Those substituents included the methoxy
(OCH3), methyl (CH3), chloro (Cl), and nitro (NO2) groups.

.
Cmpd
45a
45b
45c
45d
45e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.2: Step 1: Synthesis of Ethyl-N-phenoxyacetamidates (Maimone & Buchwald, 2010).
In the procedure, cesium carbonate (1.5 mmol), tBuBrettPhos (4 mol %),
allylpalladium(II) dimer (2 mol%), and the aryl bromide (1.0 mmol) (if solid) were added to a
roundbottom flask under argon. Once the solids were added, the aryl bromide (if liquid) was
added followed by anhydrous toluene (2.0 ml) and ethyl acetohydroxamate (1.25 mmol). The
liquids were added using a syringe while the roundbottom flask was kept under argon. The
roundbottom flask was then transferred into a preheated 65C oil bath and was left to stir for 1-4
hours (see Table 3.1) at this temperature. Most reactions were monitored using TLC. After
heating, the roundbottom flask was cooled to room temperature.
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Table 3.1:

Ethyl-N-phenoxyacetamidates reaction information.
Compound p-substituent Time (hours)
45a
45b
45d
45e

-OCH3
-CH3
-Cl
-NO2

1.5
4
1
1.5

Eluent
(hexanes:ethyl acetate)
80:20
90:10
90:10
80:20

Two short path silica gel columns were made and eluted with ethyl acetate. The mixture
was then passed through the columns. Ethyl acetate was used to transfer the mixture to the
columns and to elute the samples through the short columns. Excess ethyl acetate was removed
using the rotary evaporator after each column. Two columns were used to ensure the complete
removal of palladium and baseline materials. The crude product was purified using either column
or radial chromatography using the eluent mixture as shown in Table 3.1.
The mechanism of this organometallic reaction proceeded by an oxidative addition of the
aryl bromide (43) to the palladium catalyst (62), then cesium carbonate deprotonated the ethyl
acetohydroxamate (44) which also added to the palladium (65). Then, a cis-trans isomerization
occurred (66) and after reductive elimination, the product (45) was formed. The mechanism also
regenerated the palladium catalyst as shown in Figure 3.3.
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Cmpd
45a
45b
45c
45d
45e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.3: Mechanism converting an aryl halide to substituted ethyl-N-phenoxyacetamidates
using palladium as a catalyst.
The product, an ethyl-N-phenoxyacetamidate (45), was then hydrolyzed to form the
corresponding O-phenylhydroxylamine. This was achieved by combining the appropriately
substituted ethyl-N-phenoxyacetamidate (45) with 1,4-dioxane and hydrochloric acid as shown
in Figure 3.4 (Maimone & Buchwald, 2010).
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Cmpd
27a
27b
27c
27d
27e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.4: Synthesis of O-phenylhydroxylamines (Maimone & Buchwald, 2010)
In the procedure, the appropriately substituted ethyl N-phenoxyacetamidate (45) (0.75
mmol) was suspended in 1,4-dioxanes and was cooled in the freezer (i.e., <–5°C) until it
solidified. Then, concentrated hydrochloric acid (4.5 mmol) was added and the reaction was
warmed to room temperature. Once at room temperature, the mixture was left to stir for 1-2
hours.
The crude product was diluted with diethyl ether and extracted successively using
solutions of dilute sodium hydroxide and saturated sodium chloride (brine). After drying over
anhydrous sodium sulfate, the organic solvent was removed using the rotary evaporator. A
minimal amount of ethyl acetate was used to transfer the crude product onto a Chromatotron
plate, the ethyl acetate was allowed to evaporate, and the product was separated using radial
chromatography with either 90:10 or 80:20 hexanes:ethyl acetate (depending on the substituent,
see Table 3.1) as the eluent.
This reaction occurred via a hydrolysis mechanism forming two products: O-phenyl
hydroxylamines (27) and ethyl acetate (73), as shown in Figure 3.5.
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Cmpd
27a
27b
27c
27d
27e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.5: Hydrolysis mechanism of a substituted ethyl-N-phenoxyactamidate using
hydrochloric acid (Maimone & Buchwald, 2010). The products include the O-substituted
hydroxylamine and ethyl acetate.
Maimone and Buchwald’s method for the preparation of the O-substituted hydroxylamine
was favored because the derivatives can be made easily by purchasing aryl bromides with
different substituents. In addition, the products reported in their method were prepared in yields
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up to 91%. Other syntheses found in the literature were less favorable due to the use of
hydrazine, difficulty of purchasing starting material, and the use of a very stable phthalimide
intermediate.
Similar to the Johnson and Mosher synthesis, after the hydroxylamine (27) was made, it
was coupled to an acridine using 9-chloroacridine (59). The reaction was performed in phenol at
110 °C. A general scheme of the synthesis is shown in Figure 3.6.

Cmpd
21a
21b
21c
21d
21e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.6: Step three: Synthesis of N-(9’-acridinyl)-O-phenylhydroxylamine using 9chloroacridine and the hydroxylamine from Figure 3.1 (Johnson et al., 2018).
Phenol and the O-phenylhydroxylamine derivative (27) (1.0 mol) were heated together
until the phenol melted and the temperature stabilized between 80-100 C. Then, 9chloroacridine (59) was added and the reaction stirred for 8-12 hours. A 1.5:1 ratio of 9chloroacridine:hydroxylamine was selected for the reaction mixture to make 9-chloroacridine the
limiting reagent.
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After the solution was cooled to room temperature, the mixture was dissolved using
dichloromethane and washed successively with a dilute solution of sodium hydroxide and water.
The organic phase was then dried over anhydrous sodium sulfate and the solvent was removed
via rotary evaporation. Care was taken to ensure that at least a 1:1 mole ratio of phenol:sodium
hydroxide was used in the extraction. This ensured the complete removal of the phenol and
reduced the excessive formation of 9-hydroxyacridine that may occur due to hydrolysis of the
target compound. The products of the reaction were separated using radial chromatography with
dichloromethane and ether as the eluent.
This reaction was completed via an addition/elimination mechanism as shown in Figure
3.7. Since phenol was the solvent, the acridine was more likely to react with phenol first forming
the phenoxy ion (74-75) and displacing the chloride. Then, the hydroxylamine, a good
nucleophile, displaced the phenol (79).
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Cmpd
21a
21b
21c
21d
21e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 3.7: Addition/elimination mechanism to form N-(9’-acridinyl)-O-phenylhydroxylamines.
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The product N-(9’-acridinyl)-O-phenylhydroxylamines (21a-e) was studied using
spectroscopy. Specifically, 1H- and 2D NMR, were used to confirm the presence of the product
in the crude reaction mixture and track the isolation of the compound during chromatography.
Cmpd

R

21a

OCH3

21b
21c
21d
21e

CH3
H
Cl
NO2

Figure 3.8: Selected R groups to explore the electronic interactions of the acridines in N-(9’acridinyl)-O-phenylhydroxylamines.
Representative examples from the N-(9’-acridinyl)-O-substituted-benzylhydroxylamine
series were then evaluated for their ability to intercalate DNA using the technique of viscosity. A
calf thymus DNA solution in pH 6.3 phosphate buffer was prepared the day before it was to be
used and stored in the refrigerator overnight. This was done to minimize any effect of
decomposition of the DNA solution. The solution was then mixed with an equal amount of an
equivalent molar ratio of the acridine drug. The mixture was then inverted multiple times and
equilibrated for 2 hours at 22°C. The viscosity was then measured using the Rheosense
MicroVisc. The concentration of each DNA and drug sample was held constant so that the only
difference observed in the viscosity measurement would be due to the ability of the drug to
intercalate the DNA.
A plot of the viscosity of the acridine:DNA solutions was created to observe the
electronic effect the R group had on intercalation. The graphs were constructed with the viscosity
as the y-axis and the Hammett sigma values as the x-axis. Hammett sigma values are a
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quantitative measure of the electronic character of a substituent. As such, they can aid in
correlating the structure of a compound with a given property of that compound (such as the
ability of a drug to intercalate DNA). While the Hammett sigma values are just one method that
can provide a correlation, a full Quantitative Structure-Relationship Analysis (QSAR) could be
performed to focus on electronic, steric, and hydrophobic effects along with hydrogen bonding,
polarizability, and dipole moments. From a multivariant QSAR, the resulting impact of a
particular substituent on the intercalation of an acridine into DNA can be evaluated (Hansch &
Leo, 1995).
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CHAPTER IV
RESULTS AND DISCUSSION
Synthesis and Characterization
A series of N-(9’-acridinyl)-O-phenylhydroxylamines (21a-e) were prepared in three
steps starting with commercially available aryl bromides (43) and ethyl acetohydroxamate (44).
The first step, synthesis of ethyl-N-phenoxyacetimidates (45a-d), overall proved to be
successful. Although there was variation in this time of heating and stirring the mixture inside
the oil bath, there was little correlation to the substituent on the aryl bromide. Therefore,
monitoring the reaction using thin layer chromatography was used to determine when the
reaction was complete. In addition, after switching from flash to radial chromatography, the
separation ran more smoothly as the different products were more visible and separated more
using this system.
The substituents were chosen to span the range of electron donating to electron
withdrawing groups to study the inductive effects. To minimize the amount of variables, the
selected substituents were chosen to be only in the para position. This was to keep the reference
point the same and minimize any steric hinderance.
Maimone and Buchwald’s procedure used mainly electron neutral substituents (p-CN, ptBu, m-N(CH)3) which proved to form the product in greater yield than when using strongly
electron donating or electron withdrawing groups. These groups were electron neutral because
their Hammett Sigma values were 0.66, -0.20, and -0.15 respectively. It was observed that the
stronger electron donating and withdrawing groups needed a longer time to stir in the oil bath.
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The reaction also resulted in a noticeable amount of both the syn- and anti-product. This was
compared to the syn-: anti- ratio of the reagent used in the reaction and found to be
representative of that ratio. Because the product would be hydrolyzed to remove the oxime, the
mixture of diastereomers was treated as one unit. In addition, Maimone and Buchwald’s
procedure called for one short pad silica gel column for an initial separation. However, some
crude products, especially with ethyl-N-4-methoxyphenoxyacetamidate, showed an emerald
green color which signified that palladium was not fully removed from the crude product with
one separation. So, two short pad silica gel columns were used to completely remove excess
palladium.

Cmpd
45a
45b
45c
45d
45e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 4.1: First step of the reaction starting with an appropriately substituted aryl bromide.
The reaction to synthesize ethyl-N-phenoxyacetamidates (45a-d) provided moderate
yields (Figure 4.1). Cesium carbonate, t-BuBrettPhos, allylpalladium(II) chloride dimer, and the
appropriately substituted arylbromide (43a-d) were combined under inert gas. Then, the liquids,
toluene and ethyl acetohydroxamate (44) were added using a syringe. The mixture was kept
under inert gas while stirring in an oil bath. After heating, the color of the mixture was deep red

39
or dark brown. Solid was left on the bottom of the flask while the liquid, contacting the product,
was collected using the short pad silica gel columns. Then, the crude product was purified using
radial or flash chromatography. After chromatography, the color was tan (methyl and chloro),
deep red (methoxy) or white (nitro). The products were confirmed using NMR (see Table 4.1).
Table 4.1:
Summary of 1H NMR peaks observed for ethyl-N-phenoxyacetamidates (anti- oxime)

Compound
45a
45b
45d
45e

R
OCH3
CH3
Cl
NO2

Chemical shift of selected protons (ppm)
R
A
B
C
3.80
7.09
6.86
2.13
2.32
7.10
7.05
2.07
-7.25
7.10
2.13
-8.10
7.69
2.03

D
4.20
4.15
4.20
4.11

E
1.37
1.29
1.38
1.23

Maimone and Buchwald’s procedure noted that the product is volatile so the product
cannot be kept on the rotary evaporator for long periods of time. It was observed that this was
not the case. Using the rotary evaporator for short amounts of time to reduce the loss of the
product only resulted in large amounts of solvent in the product as evidenced by NMR
spectroscopy. Since ethyl acetate was used to separate the products, it was important to fully
evaporate the solvent to avoid ethyl acetate signals in the 1H NMR spectra which would conflict
with the oxime’s ethyl group. A COSY was used to confirm which protons corresponded to each
peak (Figure 4.2).
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C
A B

D

E

E
C

D

A

Figure 4.2: COSY of ethyl-B-4-chlorophenoxyacetamidate (45d) to confirm aromatic protons.
The red circle indicates proton B and the green circle indicates the ethyl group attachment.
The red circle shows correlation between the methyl proton and an aromatic proton. The
methyl proton, denoted as signal “C” in Figure 4.2, correlates to the more upfield aromatic
proton. This indicates that the signal denoted as “B” corresponds to the more upfield signal since
signal “B” is closer to the methyl group than the signal denoted as “A”. This was reasoned
because the proton closer to chlorine would shift that proton’s signal more downfield.
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In some cases, the 1H NMR displayed double the amount of expected peaks, for example
Figure.4.3, the peaks represented the syn- and anti-oximes resulting because the starting ethyl
acetohydroxamate was a mixture of syn- and anti- diastereomers.

Anti Addition

Syn addition

Figure 4.3: Syn- and Anti- addition of the oxime. (64% : 36%) anti-:syn- oxime. After the
products were confirmed, the data was compiled
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The syn- diastereomer is less favored due to steric hinderance. Therefore the mixture of
syn- and anti-isomers in the ethyl acetohydroxamate resulted in a similar distribution in the
product. Since these compounds displayed a nearly identical Rf value during chromatography, it
was determined that the products did not need to be separated further since the O-R bond was
formed and hydrolysis was the next step in the reaction. In some cases, the fractions obtained
during chromatography selected less or more of one of the diastereomers.
Overall, after altering some of the procedural steps, such as switching from flash
chromatography to radial chromatography or by increasing the time to obtain maximum product,
the products were made and used for the next reaction. Frequently, like products were combined
to account for the correct ratios used in the next step (see Table 4.2).
Table 4.2:

Summary of the yield and percent yield of each ethyl-N-phenoxyacetamidate derivative.
Compound
45a
45b
45d
45e

Name

Time Yield (g) Percent Yield
(h)
Ethyl N-4-methoxyphenoxyacetimidate
1.5
0.096
48
Ethyl N-4-methylphenoxyacetimidate
4
0.248
75
Ethyl N-4-chlorophenoxyacetimidate
1
0.132
65
Ethyl N-4-nitrophenoxyacetimidate
1
0.120
54

The reactions to prepare O-phenylhydroxylamines (Figure 4.4) were made in higher
yields. 1,4-Dioxane and the appropriately substituted ethyl-N-phenoxyacetamidate (45) were
mixed together and frozen. To obtain the correct ratios, multiple samples of the substituted ethylN-phenoxyacetamidate were combined using dioxane to quantitatively transfer the products
together. Hydrochloric acid was then added to the frozen mixture and the reaction stirred while
warming from 5 C to room temperature. Originally, the mixtures froze inside the ice bath (~5
C), but some derivatives, such as methoxy, nitro, and methyl, froze at -5 C.
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Cmpd
27a
27b
27c
27d
27e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 4.4: Synthesis of O-phenylhydroxylamines.
The mixture was then diluted with ether, washed with sodium hydroxide and brine, and
then dried over sodium sulfate. The tan (methyl and chloro), deep red (methoxy) or yellow
(nitro) color would stay in the organic phase during the extraction steps.
The crude product was separated using radial chromatography. The products were
identified using a handheld UV lamp. Generally, two products were detected, the more polar
compound was identified as the product and the other was unreacted starting material (45). The
completion of the reaction was enhanced by increasing the amount of stirring time both at 0 C
and at room temperature. The tan (methyl and chloro), deep red (methoxy) or off white solid
(nitro) color indicated the desired product. The product was confirmed using 1H NMR. A wide
peak around 5.5-6.5 ppm indicated that the NH2 was present (see Figure 4.5).
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D

A

B
C

Figure 4.5: 1H NMR of O-4-methylphenylhydroxylamine. Peak C at 5.845 ppm indicated the
product formed.
The NH2 peak was present in all the derivates except O-4-methoxyphenylhydroxylamine
(27a). Originally, it was predicted that removing the brine during the workup would keep more
product in the organic layer, however no improvement was observed. Since the methoxy group
donates electrons into the ring, the NH2 protons could have exchanged with deuterium. The
resulting ND2 in the 1H NMR would eliminate the expected signal. Instead, the aromatic shifts
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were observed and the lack of an ethyl group was used to determine if the product was
successfully made.
For the rest of the derivatives, a slight shift in the aromatic protons was observed (Tables
4.2 and 4.3) whereas the R group typically remained unchanged. There are no observed
correlations between which way the peaks shift.
Table 4.3:
Summary of observed 1H NMR peaks for O-phenylhydroxylamines. Parentheses represent the
shift from the corresponding ethyl-N-phenoxyacetamidate (45). *purchased from Sigma Aldrich

Compound
27a
27b
27c
27d
27e

R
OCH3
CH3
H*
Cl
NO2

R
3.81 (+0.01)
2.32 (+0.00)
6.98
---

Shifts (ppm)
A
7.40 (+0.31)
7.05 (-0.05)
7.30
7.23 (-0.02)
8.21 (+0.11)

B
6.81 (-0.05)
7.09 (+0.04)
7.16
7.10 (+0.00)
7.27 (-0.42)

C
Not observed
5.85
Not Observed
5.89
6.07

Similar to the synthesis of ethyl-N-phenoxyacetamidates, the reaction was more
successful using weak electron activating and deactivating groups (Table 4.4). Because these
prior reactions produced small amounts of product, to successfully complete the final reaction,
some of the products had to be combined to have enough starting material.
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Table 4.4:

Selected yields and percent yields of O-phenylhydroxylamines
Compound
Name
Yield (g) Percent Yield
O-(4-methoxyphenyl)hydroxylamine
0.100
23
27a
O-(4-methylphenyl)hydroxylamine
0.134
90
27b
O-(4-chlorophenyl)hydroxylamine
0.090
91
27d
O-(4-nitrophenyl)hydroxylamine
0.023
32
27e

The final step, the preparation of N-(9’acridinyl)-O-phenylhydroxylamines (21a-e), was
made by combining the appropriately substituted O-phenylhydroxylamine (27), phenol and 9chloroacridine (Figure 4.6). This was done using three different methods.

Cmpd
21a
21b
21c
21d
21e

R
-OCH3
-CH3
-H
-Cl
-NO2

Figure 4.6: Synthesis of N-(9’-acridinyl)-O-phenylhydroxylamines
The first method involved heating phenol (8.5 mmol) and the appropriately substituted Ophenylhydroxylamine (27) (1.0 mmol) together until the phenol melted. Then, 9-chloroacridine
(59) (1.2 mmol) was added and the reaction was stirred in an oil bath at 100 C for 4-6 hours.
The reaction progress was monitored using TLC. A 1.2:1 ratio of 9-
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chloroacridine:hydroxylamine was selected for the reaction mixture in order to ensure that the Ophenylhydroxylamine completely reacted. In other words, the hydroxylamine was the limiting
reagent. After the solution was cooled to room temperature, the mixture was dissolved using
dichloromethane and washed successively with a dilute solution of sodium hydroxide, water, and
brine. The organic phase was then dried over anhydrous sodium sulfate and the solvent was
removed via rotary evaporation. Care was taken to ensure that at least a 1:1 mole ratio of
phenol:sodium hydroxide was used in the extraction. This ensured the complete removal of the
phenol and reduced the excessive formation of 9-hydroxyacridine that may occur due to
hydrolysis of the target compound. The crude product was separated using radial
chromatography. A mixture of hexanes and ethyl acetate was used as the eluent.
The second method involved mixing phenol and the appropriately substituted Ophenylhydroxylamine (27) (1.5 mol) together and once the reaction stabilized between 80-100
C, 9-chloroacridine (1.0 mmol) was added. 5-Grams of phenol (59) was added for every 0.100 g
of 9-chloroacridine. This reaction was left to stir for 8-12 hours and once solidified and cooled to
room temperature, dichloromethane was used to transfer the mixture into a separatory funnel.
The reaction turned a dark red brown color. The organic layer was extracted using sodium
hydroxide and water, then dried over sodium sulfate. Portions of sodium hydroxide were added
to ensure all the phenol was removed. The more times the organic layer was extracted, the lighter
red brown the solution became. The solvent was removed using the rotary evaporator and the
crude product was a red brown solid. The products were then separated using radial
chromatography using a mixture of dichloromethane and ether as the eluent.
The third method involved mixing 9-chloroacridine (1mol) and phenol together, then
adding the appropriately substituted O-phenylhydroxylamine (27) (1.5 mol) and potassium
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carbonate (2 mol) if the hydroxylamine was a salt. 5-Grams of phenol was added for every 0.100
g of 9-chloroacridine. The reaction was stirred while the temperature was maintained between
110-120 C for 8-12 hours. Once completed, the dark colored solution was cooled to room
temperature. Chloroform was added to dissolve the reaction mixture which revealed a deep red
color. The organic phase was then washed repeatedly with dilute sodium hydroxide to remove
the phenol. During the extraction the reaction became emerald green in color that later turned
back into a deep red color as all of the phenol was removed. The crude product was then washed
with water and dried over sodium sulfate. After gravity filtration, the solvent was reduced to 1
mL using the rotary evaporator. Radial chromatography was then employed to separate the
product mixture. Typically, the chromatography revealed three tight bands—two orange and one
green. The green band appeared to contain the product.
The first and second methods produced significant amounts of 9-phenoxyacridine and 9hydroxyacridone (isolated as the acridone tautomer). Although these products were
distinguishable during separation, the target compound was difficult to isolate and appeared in
significantly smaller quantities than expected. In addition, the mixtures of hexanes and ethyl
acetate as an eluent did not completely separate the products during chromatography. In fact,
many different ratios of hexanes:ethyl acetate were used as eluents. For example, a mixture of
60:40 hexanes:ethyl acetate was used because the larger amount of ethyl acetate could help
separate the compounds. However, during the separation, the product appeared to desolvate
leading to streaking on the plate and a large reduction in the quantity formed. Mixtures as nonpolar as 98:1 hexanes:ethyl acetate were employed for the eluent, but this did not seem to
improve the solubility of the compound during chromatography.
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During most of the attempts to separate the products using radial chromatography, three
fluorescent blue fractions were observed. One of these fractions appeared to contain the product
as a mixture with other compounds. While the use of a UV-lamp could help distinguish the
individual compounds on the plate during chromatography, it was more efficient to look at the
color of the compounds under normal lighting. The first and second method showed that the first
fraction consisted of 9-phenoxyacridine, while the third fraction that had the lowest Rf consisted
of 9-acridone. This third fraction required the use of methanol containing 5% triethylamine to be
removed from the system.
The third method of preparation was the most favored over the other methods because of
the limited number and concentration of byproducts that were formed in the reaction. The
resulting chromatography was greatly improved. At least three fractions appeared as bands of
compounds with similar polarities during radial chromatography. Spectroscopy suggested that
the first fraction contained unreacted phenylhydroxylamine starting material, the second fraction
contained unreacted 9-chloroacridine, and the third fraction contained a mixture of products that
included the target compound. Often times, the crude product’s mass exceeded the ideal mass
that should be used to give a good separation of products during chromatography. Because of
this, the crude product was often split into different chromatography runs to improve the
efficiency of the isolation of the different fractions.
The identity of the compounds isolated by chromatography was determined using
spectroscopic methods. A 1H-NMR spectrum was also obtained for the starting materials,
including 9-chloroacridine and 27. A quick method for confirmation of the product using 1HNMR was to evaluate the chemical shifts of the downfield signals responsible for the acridine. A
dramatic shift in one of these signals indicated an attachment on the acridine. To predict the
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chemical shifts, other 1H NMR of other acridines were used. For example, 9-aminoacridine (83)
(Table 4.5) showed Ha and Hb at 8.47 and 7.90 ppm respectively. N-(9’-acridinyl)-Ophenylhydroxylamine (21) (Figure 4.7) showed Ha and Hb at 8.41 and 7.45 ppm respectively. It
is expected that these peaks should shift slightly based on the group attached to the amine.
Table 4.5:
1

H NMR shifts of 9-aminoacridine (83) (National Institute of Advanced Industrial Science and
Technology, n.d.).

Hydrogen Shift (ppm)
A
8.473
B
7.901
C
7.685
D
7.353
In addition, O-(ethylhydroxyl)aminoacridine was also used to predict the chemical shifts
(4.6). O-(Ethylhydroxyl)aminoacridine (84) showed Ha and Hb at 8.15 and 7.32 ppm
respectively. N-(9’-acridinyl)-O-phenylhydroxylamine (21) (Figure 4.7) showed Ha and Hb at
8.41 and 7.45 ppm respectively. An ethylhydroxylamine would provide a more accurate acridine
hydrogen prediction then 9-aminoacridine (83), however a phenyl ring would further shift the
acridine hydrogen signals.
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Table4.6:
1

H NMR shifts of 9-aminoacridine (84)

Hydrogen Shift (ppm)
A
8.15
B
6.90
C
7.53
D
7.32

N-(9’-Acridinyl)-O-phenylhydroxylamine (21c) was able to be observed within the
isolated fractions, as evidenced by spectroscopy, but was unable to be purified completely. Even
after multiple attempts, minor baseline impurities relating to other substituted acridines were
observed in the mixture (Figure 4.7).
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Figure 4.7: 1H NMR of an isolated fraction of N-(9’-acridinyl)-O-phenylhydroxylamine with the
predicted corresponding peaks
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However, 7 mg was isolated, so separating the product again would be difficult. In every
case for the other target compounds (21a, b, d, and e) the isolated fractions indicated that the
product likely had formed, but that multiple separations were unable to isolate the product. This
is likely due to the fact that the overall yield of the reaction was relatively low and the byproduct
mixture was very similar in its polarity. Because these other reactions did not provide isolated
product, the crude product yields are listed in Table 4.7.
Table 4.7:

Summary yield and percent yields of N-(9’-acridinyl)-O-phenylhydroxylamines
Compound

Name

Crude Yield
(g)

21a

N-(9’-acridinyl)-O-4methoxyphenylhydroxylamine
N-(9’-acridinyl)-O-4-methylphenylhydroxylamine
N-(9’-acridinyl)-O-phenylhydroxylamine
N-(9’-acridinyl)-O-4-chorophenylhydroxylamine
N-(9’-acridinyl)-O-4-nitroyphenylhydroxylamine

0.343

Crude
Percent
Yield
177

0.052
0.042
0.319
0.138

14
30
131
137

21b
21c
21d
21e

Viscosity Evaluation
The isolated, yet still impure N-(9’-acridinyl)-O-phenylhydroxylamine (21c) was
employed for viscosity testing. Even though this compound was not pure, it provided a reference
point to provide insight on the other compounds in the study. To prove that the viscosity
measurements could be utilized to provide a measure of the degree of intercalation, other
previously made N-(9’-acridinyl)-O-benzylhydroxylamines were included in the analysis.
Initial viscosity measurements were taken in a phosphate buffer at pH 6.0 (AAT Bioquest
Inc., n.d.). Initially, solutions of calf thymus DNA were prepared in the buffer and their
corresponding viscosity was determined. This was used to determine the optimum DNA
concentration that would be used to analyze the DNA-compound mixtures. The average of ten
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viscosity measurements was calculated for each DNA concentration. It was concluded that a
concentration of 4 x 10-5 M DNA solution would provide an adequate measure of the viscosity.
This concentration was chosen because of the exponential increase in viscosity at this
concentration, see Figure 4.8. This gave a more of a deflection in the viscosity making it easier to
measure the changes in viscosity from one derivative (21) to the next.

Figure 4.8: Initial viscosity results of calf-thymus DNA in a 0.1 M pH 6 phosphate buffer.
Using the predetermined concentration of DNA, a phosphate buffer at pH 6.3 was used to
prepare both the DNA and drug solutions. Each solution’s concentration was determined and
then diluted to a concentration of ~4 x 10-5M The DNA solution’s concentration was obtained
by UV-vis spectroscopy where the molar absorptivity (ε = 6800 /cm•M) is known at 260nm.
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Then, equal volumes of both drug and DNA solutions were combined, mixed, and allowed to
stand at room temperature for 2 hours. The DNA-drug solution was then loaded into a
microviscometer pipette and placed into the Rheosense micro-viscometer. The average and
standard deviation of 15 trials was recorded (Table 4.8). This was plotted against the Hammett
sigma values corresponding to the appropriate substituent (Figure 4.8). The viscosity of
compound 21c in DNA was also obtained, but was not included since the product was impure.
Unfortunately, the correlation between N-(9’-acridinyl)-O-benzylhydroxylamines and N-(9’acridinyl)-O-phenylhydroxylamine cannot be determined due to the impurities.
Table 4.8:

Hammett Sigma Values (Carey & Sundberg, 2007) with the corresponding viscosity
measurements at 23°C of N-(9’-acridinyl)-O-benzylhydroxylamines
Compound

Substituent

Hammett
Sigma
Value

60b
60c
60d
60d
21c

o-CH3
H
m-Cl
p-Cl
H

-0.13
0
0.37
0.23
0

Viscosity
Measurement
(average of 15
trials)
1.130
1.420
1.175
1.123
1.363

Standard
Deviation

0.081
0.090
0.018
0.026
0.042
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Figure 4.9: Plot of Hammett Sigma values and the viscosity measurements
Figure 4.9 provides the observed relationship of viscosity to the Hammett sigma values
for the substituents. The correlation is not very good (R2 value of 0.0216), and it can be
concluded that if the viscosity is a good measure of the intercalation of the compound, the effect
of substitution of this class of compound is not well described by the Hammett sigma values. In
fact, the unsubstituted molecule in this series has the greatest effect on viscosity. And because a
higher viscosity would indicate a greater amount of intercalation, the unsubstituted molecule
should have the greatest amount of intercalation.
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CHAPTER V
CONCLUSIONS
Ethyl-N-phenoxyacetamidates and O-phenylhydroxylamines were made with moderate
yields. However, the title compound (21a-e) was challenging to prepare and separate. The most
electron withdrawing substituent (nitro) proved to be the easiest to monitor and work with during
the reactions. This was mostly due to the nitro series being a solid making it easier to remove the
solvents. However, each reaction made portions of the product which, after lots of practice, was
easily separated using radial chromatography. Compared to other hydrolysis reactions, using
hydrochloric acid and dioxanes seemed to be a straightforward and less harmful way to remove
the protecting group off the oxime. With slightly longer reaction times, this method was very
successful and allowed for the amine to form rather than the salt (NH3 and HCl). This was
helpful in the final synthesis because a weak base could be omitted leaving one less variable to
overcome.
Although the first few products were successfully made and purified, the title compound
(21a-e) was challenging to prepare and separate. Figure 4.7 shows that the product was made,
but was not completely separated. However, this fraction contained only 7 mg of product, so
further purification would be tough. If other product was made, the yield was also very low,
again, making chromatography difficult. In addition, byproducts from the reaction contained a
similar Rf to the target compound making separation even more challenging. Many methods
were used to try and separate the crude mixture and using a mixture of dichloromethane and
ether seemed to be the most optimal. Using more starting material could be beneficial to make
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chromatography easier. More starting material would produce more crude product allowing the
same fraction of product to be separated multiple times. Future work includes purifying the title
compounds further and confirming the products using 1D and 2D spectroscopy.
In addition to the development of other methods to fully isolate the target compounds and
improve their purity and yield, future work would suggest that additional biological testing is
needed to further study this series of compounds more in depth. Initial viscosity measurements
were taken to determine the concentration of DNA needed to optimize the viscosity. A DNA
concentration of 4 x 10-4 M showed large variances in the viscosity whereas 1 x 10-5 would show
little to no variance. Preparing DNA solutions with this concentration in a 0.01 M phosphate
buffer at pH 6.0 would provide optimal parameters to evaluate the effects different substituents
have on intercalation.
Another biological test for this series of compounds could be to evaluate and determine
their effect on the transition temperature of double-stranded DNA to single-stranded DNA. That
would give additional information about how well each compound is at binding with DNA and
how effective these compounds are at altering the DNA. Another analysis could be made in vitro
by studying how effective these compounds are at inhibiting the growth of a given cell line.
After this method is optimized, other derivatives could be made and tested further. Other
derivatives could be made, such as NR2, alkene, or a nitrile group, in different positions such as
ortho and meta or a combination of positions. This series of compounds should also span from
different electron donating and electron withdrawing groups.

59

REFERENCES
AAT Bioquest Inc. (n.d.). Phosphate Buffer (pH 5.8 to 7.4). Retrieved from
https://www.aatbio.com/resources/buffer-preparations-and-recipes/phosphate- buffer-ph5-8-to-7-4,
American Cancer Society. (2014a). Cancer in the Twenty-first Century.
https://www.cancer.org/cancer/cancer-basics/history-of-cancer/twenty-first-century- andbeyond.html\
American Cancer Society. (2014b). Early History of Cancer.
https://www.cancer.org/cancer/cancer-basics/history-of-cancer/what-is-cancer.html
Belmont, P., & Dorange, I. (2008). Acridine/acridone: A simple scaffold with a wide range of
application in oncology. Expert Opinion on Therapeutic Patents, 18(11), 1211–1224.
https://doi.org/10.1517/13543776.18.11.1211
Carey, F., & Sundberg, R. (2007). Linear Free-Energy Relationships for Substituent Effects. In
Advanced Organic Chemistry Part A: Structure and Mechanisms (Fifth). Springer
Science+Business Media, LLC.
Castellino, A. J., & Rapoport, H. (1984). Synthesis of phenoxyamines. The Journal of Organic
Chemistry, 49(8), 1348–1352. https://doi.org/10.1021/jo00182a007
Centers for Disease Control and Prevention. (2018). Expected New Cancer Cases and Deaths in
2020. Retrieved from
https://www.cdc.gov/cancer/dcpc/research/articles/cancer_2020.htm

60
Chemical Book. (n.d.). (O-Benzylhydroxylamine) Product Description. Retrieved from
https://www.chemicalbook.com/ChemicalProductProperty_US_CB6853994.aspx
Denny. (2002). Acridine Derivatives as Chemotherapeutic Agents. Current Medicinal Chemistry,
9(18). https://doi.org/10.2174/0929867023369277
Gao, C., Li, B., Zhang, B., Sun, Q., Li, L., Li, X., Chen, C., Tan, C., Liu, H., & Jiang, Y. (2015).
Synthesis and biological evaluation of benzimidazole acridine derivatives as potential
DNA- binding and apoptosis-inducing agents. Bioorganic & Medicinal Chemistry,
23(8), 1800–1807. https://doi.org/10.1016/j.bmc.2015.02.036
Gaucher-Wieczorek, F. S., Maillard, L. T., Badet, B., & Durand, P. (2010). Fluorous Tagged NHydroxy Phthalimide for the Parallel Synthesis of O -Aryloxyamines. Journal of
Combinatorial Chemistry, 12(5), 655–658. https://doi.org/10.1021/cc100098v
Ghosh, R., & Olofsson, B. (2014). Metal-Free Synthesis of N -Aryloxyimides and
Aryloxyamines. Organic Letters, 16(6), 1830–1832. https://doi.org/10.1021/ol500478t
Hansch, C., & Leo, A. (1995). Exploring QSAR Fundamentals and Applications in Chemistry
and Biology. American Chemical Society.
Horning, E. C., Allen, C. F. H., Drake, N. L., Hamilton, C. S., Shriner, R. L., Smith, L. I., &
Snyder, H. (Eds.). (1955). Organic Synthesis Collective Volume 3. In Organic
Syntheses (20th–29th ed., Vol. 3, pp. 53–54). New York, Chichester, Brisbane,
Toronto: John Wiley & Sons.
Johnson, A. L., Duncan, N., & Mosher, M. D. (2018). O-Benzyl-N-(9-acridinyl)hydroxylamines.
Arkivoc, 2018(4), 139–148. https://doi.org/10.24820/ark.5550190.p010.472

61
Kerby, M., & Mosher, M. D. (2016). Interactions between O-benzyl-N-(9’acridinyl)hydroxylamines and Calf Thymus DNA: An Evaluation of Drug Intercalation
as a measure of Viscosity. Whitepaper.
Ketron, A. C., Denny, W. A., Graves, D. E., & Osheroff, N. (2012). Amsacrine as a
Topoisomerase II Poison: Importance of Drug–DNA Interactions. Biochemistry, 51(8),
1730–1739. https://doi.org/10.1021/bi201159b
Kumar, R., Sharma, A., Sharma, S., Silakari, O., Singh, M., & Kaur, M. (2017). Synthesis,
characterization and antitumor activity of 2-methyl-9-substituted acridines. Arabian
Journal of Chemistry, 10, S956–S963. https://doi.org/10.1016/j.arabjc.2012.12.035
Lerman, L. S. (1961). Structural considerations in the interaction of DNA and acridines. 3, 15.
Lodish, H., Berk, A., Zipursky, S. L., Matsudaira, P., Baltimore, D., & Darnell, J. (2000). The
Role of Topoisomerases in DNA Replication. Molecular Cell Biology. 4th Edition.
Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK21703/
Maimone, T. J., & Buchwald, S. L. (2010). Pd-Catalyzed O-Arylation of Ethyl
Acetohydroximate: Synthesis of O -Arylhydroxylamines and Substituted Benzofurans.
Journal of the American Chemical Society, 132(29), 9990–9991.
https://doi.org/10.1021/ja1044874
National Institute of Advanced Industrial Science and Technology. (n.d.). Spectral Database for
Organic Compounds. Retrieved from https://sdbs.db.aist.go.jp/
Patrick, G. (2005). An Introduction to Medicinal Chemistry (3rd ed.). Oxford University Press.
Petrassi, H. M., Sharpless, K. B., & Kelly, J. W. (2001). The Copper-Mediated Cross-Coupling
of Phenylboronic Acids and N -Hydroxyphthalimide at Room Temperature: Synthesis
of Aryloxyamines. Organic Letters, 3(1), 139–142. https://doi.org/10.1021/ol0003533

62
Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal
for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590
Sigma Aldrich. (n.d.). Protocol Guide: MTT Assay for Cell Viability and Proliferation. Retrieved
from https://www.sigmaaldrich.com/technical-documents/protocols/biology/roche/cellproliferation-kit-i-mtt.html
Wilson, W. D., Keel, R. A., Jones, R. L., & Mosher, C. W. (1982). Viscometric analysis of the
interaction of bisphenanthridinium compounds with closed circular supercoiled and
linear DNA. Nucleic Acids Research, 10(13), 4093–4106.
Zhang, S., Sun, X., Kong, R., & Xu, M. (2015). Studies on the interaction of apigenin with calf
thymus DNA by spectroscopic methods. Spectrochimica Acta Part A: Molecular and
Biomolecular Spectroscopy, 136, 1666–1670. https://doi.org/10.1016/j.saa.2014.10.062

63

APPENDIX A
EXPERIMENTAL DATA
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Substituted aryl bromides and (the unsubstituted) O-phenylhydroxylamine were
purchased from Sigma Aldrich and were used without further purification. NMR spectra were
obtained using a Bruker Avance II, 400 MHz. 1H NMR were taken for each product to confirm
the structure of the product.
General Procedure for the Preparation of Ethyl-N-phenoxyacetamidates (45a,b,d,e)
An oven-dried 25 ml roundbottom flask filled with argon and 490 mg of cesium
carbonate (1.5 mmol, 1.5 equiv) was added followed by 4 mg of (allylPdCl)2 (2 mol %), 19 mg
of tBuBrettPhos (4 mol %), and the aryl halide (if solid) (1.0 mmol, 1.0 equiv). The roundbottom
flask was continuously filled with argon and sealed. To the sealed flask, the aryl halide was
added (if liquid) followed by 2.0 ml of anhydrous toluene, and 0.12 ml of ethyl
acetohydroxamate (1.25 mmol, 1.25 equiv.). The roundbottom flask was then transferred into a
preheated 65C oil bath and was left to stir for 1-4 hours (see Table 3.1) at this temperature.
Most reactions were monitored using TLC. After heating, the roundbottom flask was cooled to
room temperature. Radial chromatography was used to separate the products.

Ethyl-N-4-methoxyphenoxyacetamidate (45a)
48% yield. 1H NMR (400 MHz, CDCl3) in , 7.09 (d, J = 8.2 Hz, 2H); 6.86 (d, J = 8.2 Hz,
2H); 4.20 (q, J = 7.0 Hz, 2H); 3.80 (s, 3H); 2.13 (s, 3H); 1.37 (t, J = 7.0 Hz, 3H) ppm. 13C NMR
(400 MHz, CDCl3) in , 165.3; 154.2; 153.9; 115.0; 114.4; 62.8; 55.8; 14.4; 14.2 ppm.
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Ethyl-N-4-methylphenoxyacetamidate (45b)
57% yield. 1H NMR (400 MHz, CDCl3) in , 7.11 (d, J = 8.6 Hz, 2H); 7.06 (d, J = 8.6
Hz, 2H); 4.22 (q, J = 7.1 Hz, 2H); 2.32 (s, 3H); 2.14 (s, 3H); 1.38 (t, J = 7.1 Hz, 3 H) ppm. 13C
NMR (400 MHz, CDCl3),  165.4; 157.7; 130.4; 129.6; 113.8; 62.8; 20.8; 14.4; 14.2 ppm.

Ethyl-N-4-chlorophenoxyacetamidate (45d)
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91% yield. (CDCl3) Spectroscopically identical to the literature values for this compound
(Maimone & Buchwald, 2010)

Ethyl-N-4-nitrophenoxyacetamidate (45e)
54% yield. 1H NMR (400 MHz, CDCl3)  8.22 (d, J = 9.2 Hz, 2H); 7.25 (d, J = 9.2 Hz,
2H); 4.24 (q, J = 72 Hz, 2H); 1.40 (t, J = 7.1 Hz, 3H) ppm.

General Procedure for the Preparation
of O-phenylhydroxylamines (27a,b,d,e)
A 25-100 ml roundbottom flask was filled with 0.75 mmol (1 equiv) of the appropriately
substituted ethyl-N-4-methoxyphenoxyacetimidate followed by 1.5 ml of 1,4-dioxane. If
multiple ethyl-N-4-methoxyphenoxyacetimidate samples were used, 1,4-dioxanes were used to
quantitatively transfer each solution. The roundbottom flask was then capped and placed in the
freezer until the mixture solidified (about 20 minutes). After the mixture froze, the roundbottom
was removed from the freezer and placed in an icebath. Then, 4.5 mmol of concentrated
hydrochloric acid was added (6 M aqueous solution, 750 l, 6 equiv) and the reaction was left to
stir for 10 minutes. At this point, the solution became a liquid and the liquid was warmed to
room temperature and was left to stir for 2 h at room temperature. Then the mixture was diluted
with 10 ml of diethyl ether (Et2O) which was then added to 25 ml of 1 M NaOH in a 125 ml
separatory funnel. The aqueous layer was extracted using 2 x 10 ml of diethyl ether and the
organic layers were combined. The organic layer was washed with 25 ml of 1 M NaOH followed
by 25 ml brine, and dried over sodium sulfate. The solvent was removed using the rotary
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evaporator. The crude products were separated using radial chromatography. 90:10 or 80:20
Hexanes: ethyl acetate was used depending on what the product’s solubility (see Table 3.1).
Portions of ethyl acetate were added to move the products down the silica gel plate. TLC was
used to identify the fractions and like products were combined and the solvent was removed
using the rotary evaporator.

O-(4-methoxyphenyl)hydroxylamine (27a)
23 % yield. 1H NMR (400 MHz, CDCl3)  7.40 (d, J = 8.6 Hz, 2H); 6.81 (d, J = 8.6 Hz,
2H); 3.81 (s, 3H) ppm.

O-(4-methylphenyl)hydroxylamine (27b)
90 % yield. 1H NMR (400 MHz, CDCl3) in , 7.09 (d, J= 8.4 Hz, 2H); 7.05 (d, J = 8.4 Hz,
2H); 5.85 (s, 2H); 2.32 (s, 3H) ppm. 13C NMR (400 MHz, CDCl3),  159.2; 130.3; 129.7; 113.0;
20.5 ppm.
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O-(4-chlorophenyl)hydroxylamine (27d)
Percent Yield: 91% Agrees with literature (Maimone & Buchwald, 2010)

O-(4-nitrophenyl)hydroxylamine (27e)
32 % yield. 1H NMR (400 MHz, CDCl3)  8.21 (d, J = 9.2 Hz, 2H); 7.27 (d, J = 9.2 Hz,
2H); 6.07 (s, 2H) ppm.
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General Procedure for the Preparation of
N-(9’-Acridinyl)-O-phenylhydroxylamines
(21a-e)
To a 50 ml roundbottom flask, 9-chloroacridine and phenol were added followed by the
substituted O-phenylhydroxylamine and potassium carbonate (if the hydroxylamine was a salt).
The reaction was heated between 110-120 C for 8-12 hours. A 1.5:1 mol Ophenylhydroxylamine:9-chloroacridine ratio was used to selectively make 9-chloroacridine the
limiting reagent. 5-Grams of phenol was used for every 0.100 g of 9-chloroacridine used. Once
cooled to room temperature, 30-50 ml of chloroform was used to transfer the products into a 250
ml separatory funnel with 100 ml of 0.1 M NaOH. The organic layer was extracted and washed
with an additional 5 x 100 ml of 0.1 M NaOH or until there was no trace scent of phenol. (100
ml of NaOH was used for every 0.1 g of 9-chloroacridne used). After all the excess phenol was
removed, the organic layer was extracted with 100 ml of DI water and dried over sodium sulfate
for 10 minutes. The crude product was gravity filtered to remove the sodium sulfate. Excess
solvent was removed using the rotary evaporator to obtain approximately 1 ml of crude product
suspended in the solvent.
The crude product was separated using radial chromatography. A 2 mm silica gel plate
eluted with dichloromethane and triethyl amine. Portions of ether were used to separate the three
main products. Like fractions were combined using TLC and the solvent was removed using the
rotary evaporator.
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N-(9’-acridinyl)-O-(4-methoxyphenyl)hydroxylamine (21a)
Crude Yield: 0.343 g Crude Percent Yield: 177 %

N-(9’-acridinyl)-O-(4-methylphenyl)hydroxylamine (21b)
Crude Yield: 0.052 g Crude Percent Yield: 14 %

N-(9’-acridinyl)-O-phenylhydroxylamine (21c)
Crude Yield: 0.042 g Crude Percent Yield: 30 % Crude 1H NMR 8.42, 7.61, 7.45, 7.34,
7.22, 7.18, 6.88, 6.83, and 6.81 ppm contain 21c but the product could not be isolated any
further.
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N-(9’-acridinyl)-O-(4-chlorophenyl)hydroxylamine (21d)
Crude Yield: 0.319 g Crude Percent Yield: 131 %
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N-(9’-acridinyl)-O-(4-nitrophenyl)hydroxylamine (21e)
Crude Yield: 0.138 g Crude Percent Yield: 137 %
General Procedure for Measuring Viscosity
To measure the viscosity of a solution, a phosphate buffer at pH 6.3, calf thymus DNA,
and the appropriately substituted N-(9’-acridinyl)-O-benzylhydroxylamine and N-(9’-acridinyl)O-phenylhydroxylamine was needed. To prepare a phosphate buffer, 0.184 g of sodium
phosphate dibasic heptahydrate was added to 400 ml of distilled water followed by 0.585 g of
sodium phosphate monobasic monohydrate. Then, 100 ml of distilled water was added to make a
0.5 L phosphate buffer solution. 0.010 g of the appropriately substituted N-(9’-acridinyl)-Ophenylhydroxylamine was suspended in the phosphate buffer and 1 mg of calf thymus DNA
added. The DNA concentration was kept at 4 x 10-5 M to measure the viscosity changes. The
average of 15 viscosity measurements was recorded using a RheoSense MicroViscometer.

